MF Researcher Database

研究者一覧

詳細

有泉　裕嗣Ariizumi Hirotsugu

■所属部署名腫瘍内科
■職名講師
Last Updated :2025/04/01

研究者情報

基本情報

プロフィール情報

  • 氏名

    有泉　裕嗣, Ariizumi Hirotsugu

所属

  • 腫瘍内科, 講師

施設

  • 大学病院

学位

  • 博士(医学), 昭和大学, 2012年03月

研究キーワード

  • 血液、腫瘍

業績

論文

  • がん遺伝子パネル検査からみえる昭和大学病院のがんゲノム医療の課題, 竹内　抄與子;吉田　玲子;有泉　裕嗣;桑山　隆志;角田　卓也;中村　清吾, 昭和学士会雑誌, 84(1):82 - 93, 2024年03月, 原著, 査読あり, DOI:https://doi.org/10.14930/jshowaunivsoc.84.82
  • Novel quantitative immunohistochemical analysis for evaluating PD-L1 expression with phosphor-integrated dots for predicting the efficacy of patients with cancer treated with immune checkpoint inhibitors., Ohkuma R, Miura S, Muto S, Toyomasu Y, Fujimoto Y, Ieguchi K, Onishi N, Shimizu T, Watanabe M, Takayanagi D, Goshima T, Horiike A, Hamada K, Ariizumi H, Shimokawa M, Hirasawa Y, Ishiguro T, Suzuki R, Iriguchi N, Tsurui T, Mura E, Takenoshita S, Numajiri K, Okabe N, Yoshimura K, Tsuji M, Kiuchi Y, Yajima T, Ishida H, Suzuki H, Yamochi T, Kobayashi S, Tsunoda T, Wada S., Front Immunol, 14:1260492, 2023年09月, 原著, 査読あり, DOI:10.3389/fimmu.2023.1260492
  • Turicibacter and Acidaminococcus predict immune-related adverse events and efficacy of immune checkpoint inhibitor., Kazuyuki Hamada, Junya Isobe, Kouya Hattori, Masahiro Hosonuma, Yuta Baba, Masakazu Murayama, Yoichiro Narikawa, Hitoshi Toyoda, Eiji Funayama, Kohei Tajima, Midori Shida, Yuya Hirasawa, Toshiaki Tsurui, Hirotsugu Ariizumi, Tomoyuki Ishiguro, Risako Suzuki, Ryotaro Ohkuma, Yutaro Kubota, Takehiko Sambe, Mayumi Tsuji, Satoshi Wada, Yuji Kiuchi, Shinichi Kobayashi, Atsuo Kuramasu, Atsushi Horiike, Yun-Gi Kim, Takuya Tsunoda and Kiyoshi Yoshimura, Front Immunol., 14:1164724, 2023年05月, 原著, 査読あり, DOI:10.3389/fimmu.2023.1164724
  • Minimal contribution of the hepatic uptake transporter OATP1B1 to the inter-individual variability in SN-38 pharmacokinetics in cancer patients without severe renal failure., TSUBOYA Ayako;KUBOTA Yutaro;ISHIDA Hiroo;OHKUMA Ryotaro;ISHIGURO Tomoyuki;HIRASAWA Yuya;ARIIZUMI Hirotsugu;TSUNODA Takuya;SASAKI Yasutsuna;MATSUMOTO Natsumi;KONDO Yusuke;TOMODA Yukana;KUSUHARA Hiroyuki;FUJITA Ken-ichi, Cancer Chemother Pharmacol, :e, 2021年06月, 原著, 査読あり
  • The Prognostic Impact of Eosinophils and the Eosinophil-to-Lymphocyte Ratio on Survival Outcomes in Stage II Resectable Pancreatic Cancer., Ohkuma Ryotaro;Kubota Yutaro;Horiike Atsushi;Ishiguro Tomoyuki;Hirasawa Yuya;Ariizumi Hirotsugu;Watanabe Makoto;Onoue Rie;Ando Kiyohiro;Tsurutani Junji;Yoshimura Kiyoshi;Aoki Takeshi;Murakami Masahiko;Kobayashi Shinichi;Tsunoda Takuya;Wada Satoshi, Pancreas, 50(2), 2021年, 原著, 査読あり
  • Rare Nivolumab-associated Super Hyper Progressive Disease in Patients With Advanced Gastric Cancer., Kubota Yutaro;Yoshimura Kiyoshi;Hamada Kazuyuki;Hirasawa Yuya;Shida Midori;Taniguchi Makoto;Matsui Hiroto;Ariizumi Hirotsugu;Ishiguro Tomoyuki;Suzuki Norihiro;Ohkuma Ryotaro;Sambe Takehiko;Ishida Hiroo;Horiike Atsushi;Wada Satoshi;Tsurutani Junji;Iwamoto Sanju;Uchida Naoki;Kiuchi Yuji;Kobayashi Shinichi;Tsunoda Takuya, In vivo (Athens, Greece), 35(3), 2021年, 原著, 査読あり
  • A case report on severe nivolumab-induced adverse events similar to primary sclerosing cholangitis refractory to immunosuppressive therapy., Hirasawa Yuya;Yoshimura Kiyoshi;Matsui Hiroto;Kubota Yutaro;Ishida Hiroo;Arai Jun;Sakaki Masashi;Oguro Nao;Shida Midori;Taniguchi Makoto;Hamada Kazuyuki;Ariizumi Hirotsugu;Ishiguro Tomoyuki;Ohkuma Ryotaro;Sambe Takehiko;Horiike Atsushi;Imamura Chiyo K;Shiozawa Eisuke;Wada Satoshi;Tsurutani Junji;Iwamoto Sanju;Uchida Naoki;Kiuchi Yuji;Tate Genshu;Kobayashi Shinichi;Tsunoda Takuya, Medicine, 100(23), 2021年, 原著, 査読あり
  • A high number of PD-L1+ CD14+ monocytes in peripheral blood is correlated with shorter survival in patients receiving immune checkpoint inhibitors., Ando Kiyohiro;Hamada Kazuyuki;Shida Midori;Ohkuma Ryotaro;Kubota Yutaro;Horiike Atsushi;Matsui Hiroto;Ishiguro Tomoyuki;Hirasawa Yuya;Ariizumi Hirotsugu;Watanabe Makoto;Onoue Rie;Tsurutani Junji;Yoshimura Kiyoshi;Tsunoda Takuya;Kobayashi Shinichi;Wada Satoshi, Cancer immunology, immunotherapy : CII, 70(2), 2020年08月, 原著, 査読あり
  • Variants of carboxylesterase 1 have no impact on capecitabine pharmacokinetics and toxicity in capecitabine plus oxaliplatin treated-colorectal cancer patients, MATSUMOTO Natsumi;KUBOTA Yutaro;ISHIDA Hiroo;SEKIDO Masae;OHKUMA Ryotaro;ISHIGURO Tomoyuki;HIRASAWA Yuya;ARIIZUMI Hirotsugu;TSUNODA Takuya;IKUSUE Toshikazu;KOBAYASHI Kouji;HISAMATSU Atsushi;TOSHIMA Hirokazu;SHIMADA Ken;FUJITA Ken-ichi, Cancer Chemother Pharmacol, 85(6):1119 - 1128, 2020年06月, 原著, 査読あり
  • High expression of olfactomedin-4 is correlated with chemoresistance and poor prognosis in pancreatic cancer., OHKUMA Ryotaro;YADA Erica;ISHIKAWA Shumpei;KOMURA Daisuke;ISHIZAKI Hidenobu;TAMADA Koji;KUBOTA Yutaro;HAMADA Kazuyuki;ISHIDA Hiroo;HIRASAWA Yuya;ARIIZUMI Hirotsugu;SATOH Etsuko;SHIDA Midori;WATANABE Makoto;ONOUE Rie;ANDO Kiyohiro;TSURUTANI Junji;YOSHIMURA Kiyoshi;YOKOBORI Takehiko;SASADA Tetsuro;AOKI Takeshi;MURAKAMI Masahiko;NOROSE Tomoko;OHIKE Nobuyuki;TAKIMOTO Masafumi;IZUMIZAKI Masahiko;KOBAYASHI Shinichi;TSUNODA Takuya;WADA Satoshi, PloS One, 15(1):e0226707, 2020年01月, 原著, 査読あり
  • Agranulocytosis During Treatment With Sulfamethoxazole-Trimethoprim and a Proton Pump Inhibitor, FUNAKOSHI Haruki;MOMO Kenji;UCHIKURA Takeshi;ARIIZUMI Hirotsugu;HAMADA Kazuyuki;TSUNODA Takuya;SASAKI Tadanori, Am J Ther, :1 - 3, 2019年11月, 原著, 査読あり
  • Agranulocytosis During Treatment With Sulfamethoxazole-Trimethoprim and a Proton Pump Inhibitor, FUNAKOSHI Haruki;MOMO Kenji;UCHIKURA Takeshi;ARIIZUMI Hirotsugu;HAMADA Kazuyuki;TSUNODA Takuya;SASAKI Tadanori, Am J Ther, :1 - 3, 2019年11月, 原著, 査読あり
  • Plasma Levels of Soluble PD-L1 Correlate With Tumor Regression in Patients With Lung and Gastric Cancer Treated With Immune Checkpoint Inhibitors, ANDO Kiyohiro;HAMADA Kazuyuki;WATANABE Makoto;OHKUMA Ryotaro;SHIDA Midori;ONOUE Rie;KUBOTA Yutaro;MATSUI Hiroto;ISHIGURO Tomoyuki;HIRASAWA Yuya;ARIIZUMI Hirotsugu;TSURUTANI Junji;YOSHIMURA Kiyoshi;TSUNODA Takuya;KOBAYASHI Shinichi;WADA Satoshi, Anticancer Res, 39(9):5195 - 5201, 2019年09月, 原著, 査読あり
  • Plasma Levels of Soluble PD-L1 Correlate With Tumor Regression in Patients With Lung and Gastric Cancer Treated With Immune Checkpoint Inhibitors, ANDO Kiyohiro;HAMADA Kazuyuki;WATANABE Makoto;OHKUMA Ryotaro;SHIDA Midori;ONOUE Rie;KUBOTA Yutaro;MATSUI Hiroto;ISHIGURO Tomoyuki;HIRASAWA Yuya;ARIIZUMI Hirotsugu;TSURUTANI Junji;YOSHIMURA Kiyoshi;TSUNODA Takuya;KOBAYASHI Shinichi;WADA Satoshi, Anticancer Res, 39(9):5195 - 5201, 2019年09月, 原著, 査読あり
  • 腎癌および尿路上皮癌患者におけるバイオマーカー探索のための腸内細菌叢の研究, 下山　英明;直江　道夫;サト　プラサド　ネパール;平松　綾;松井　祐輝;鵜木　勉;中里　武彦;押野見　和彦;森田　順;前田　佳子;冨士　幸藏;小川　良雄;角田　卓也;吉村　清, 昭和学士会雑誌, 79(4):492 - 504, 2019年08月, 原著, 査読あり
  • Status of Natural Killer Cell Recovery in Day 21 Bone Marrow after Allogeneic Hematopoietic Stem Cell Transplantation Predicts Clinical Outcome., HATTORI Norimichi;SAITO Bungo;SASAKI Yohei;SHIMADA Shotaro;MURAI So;ABE Maasa;BABA Yuta;WATANUKI Megumi;FUJIWARA Shun;KAWAGUCHI Yukiko;ARAI Nana;KABASAWA Nobuyuki;TSUKAMOTO Hiroyuki;UTO Yui;ARIIZUMI Hirotsugu;YANAGISAWA Kouji;HARADA Hiroshi;NAKAMAKI Tsuyoshi, Biol Blood Marrow Transplant, 24(9):1841 - 1847, 2018年09月, 原著, 査読あり
  • Association of red cell distribution width with clinical outcomes in myelodysplastic syndrome., BABA Yuta;SAITO Bungo;SHIMADA Shotaro;SASAKI Yohei;MURAI So;ABE Maasa;FUJIWARA Shun;ARAI Nana;KAWAGUCHI Yukiko;KABASAWA Nobuyuki;TSUKAMOTO Hiroyuki;UTO Yui;ARIIZUMI Hirotsugu;YANAGISAWA Kouji;HATTORI Norimichi;HARADA Hiroshi;NAKAMAKI Tsuyoshi, Leuk Res, 67:56 - 59, 2018年04月, 原著, 査読あり
  • Association of Soluble Interleukin-2 Receptor and C-Reactive Protein with the Efficacy of Bendamustine Salvage Treatment for Indolent Lymphomas and Mantle Cell Lymphoma., KAWAGUCHI Yukiko;NAKAMAKI Tsuyoshi;ABE Maasa;BABA Yuta;MURAI So;WATANUKI Megumi;ARAI Nana;FUJIWARA Shun;KABASAWA Nobuyuki;TSUKAMOTO Hiroyuki;UTO Yui;ARIIZUMI Hirotsugu;YANAGISAWA Kouji;HATTORI Norimichi;HARADA Hiroshi;SAITO Bungo, Acta Haematol, 139(1):12 - 18, 2018年02月, 原著, 査読あり
  • Efficacy of palonosetron to prevent delayed nausea and vomiting in non-Hodgkin's lymphoma patients undergoing repeated cycles of the CHOP regimen., SAITO Bungo;NAKASHIMA Hidetoshi;ABE Maasa;MURAI So;BABA Yuta;ARAI Nana;KAWAGUCHI Yukiko;FUJIWARA Shun;KABASAWA Nobuyuki;TSUKAMOTO Hiroyuki;UTO Yui;ARIIZUMI Hirotsugu;YANAGISAWA Kouji;HATTORI Norimichi;HARADA Hiroshi;NAKAMAKI Tsuyoshi, Support Care Cancer, 26(1):269 - 274, 2018年01月, 原著, 査読あり
  • Post-cytokine-release salt wasting as inverse tumor lysis syndrome in a non-cerebral natural killer-cell neoplasm, ARIIZUMI Hirotsugu;SASAKI Yosuke;HARADA Hiroshi;UTO Yui;AZUMA Remi;ISOBE Tomohide;KISHIMOTO Koji;SHIOZAWA Eisuke;TAKIMOTO Masafumi;OHIKE Nobuyuki;MORI Hiraku, Intern Med, 56(14):1855 - 1861, 2017年07月, 原著, 査読あり
  • Umbilical cord blood transplantation for adults using tacrolimus with two-day very-short-term methotrexate for graft-versus-host disease prophylaxis, SAITO Bungo;HATTORI Norimichi;YAMAMOTO Kohei;ARAI Nana;KAWAGUCHI Yukiko;FUJIWARA Shun;KABASAWA Nobuyuki;TSUKAMOTO Hiroyuki;UTO Yui;ARIIZUMI Hirotsugu;YANAGISAWA Kouji;NAKAMAKI Tsuyoshi, Leuk Res, 47:161 - 165, 2016年08月, 原著, 査読あり
  • Age and Bone Marrow Cellularity are Associated with Response to Eltrombopag in Japanese Adult Immune Thrombocytopenia Patients: A Retrospective Single-Center Study., UTO Yui;FUJIWARA Shun;ARAI Nana;KAWAGUCHI Yukiko;KABASAWA Nobuyuki;TSUKAMOTO Hiroyuki;ARIIZUMI Hirotsugu;HATTORI Norimichi;SAITO Bungo;YANAGISAWA Kouji;HARADA Hiroshi;MORI Hiraku;SHIOZAWA Eisuke;NAKAMAKI Tsuyoshi, 臨床病理, 63(5):548 - 556, 2015年05月, 原著, 査読あり
  • Predictive role of levels of soluble interleukin-2 receptor and C-reactive protein in selecting autologous PBSC transplantation for lymphoma, ARIIZUMI Hirotsugu;SAITO Bungo;UTO Yui;HATTORI Norimichi;NAKASHIMA Hidetoshi;YANAGISAWA Kouji;HARADA Hiroshi;MORI Hiraku;NAKAMAKI Tsuyoshi, Bone Marrow Transplant, 50(2):301 - 303, 2015年02月, 査読あり
  • CD20 gene deletion causes a CD20-negative relapse in diffuse large B-cell lymphoma., NAKAMAKI Tsuyoshi;FUKUCHI Kunihiko;NAKASHIMA Hidetoshi;ARIIZUMI Hirotsugu;MAEDA Takashi;SAITO Bungo;YANAGISAWA Kouji;TOMOYASU Shigeru;HOMMA Mayumi;SHIOZAWA Eisuke;YAMOCHI-ONIZUKA Toshiko;OTA Hidekazu, Eur J Haematol, 89(4):350 - 355, 2012年10月, 原著, 査読あり
  • Retrospective Analysis of Clinical Factors Relating to the Outcome of Gemtuzumab Ozogamicin Therapy, ARIIZUMI Hirotsugu;SAITO Bungo;NAKASHIMA Hidetoshi;HATTORI Norimichi;MAEDA Takashi;NAKAMAKI Tsuyoshi;TOMOYASU Shigeru, Showa Univ J Med Sci, 23(2):75 - 87, 2011年06月, 原著, 査読あり, DOI:10.15369/sujms.23.75
  • p53 protein expression in chronic myelomonocytic leukemia-1 correlates with progression to leukemia and a poor prognosis, HATTORI Norimichi;FUKUCHI Kunihiko;NAKAMAKI Tsuyoshi;ARIIZUMI Hirotsugu;NAKASHIMA Hidetoshi;MAEDA Takashi;SAITO Bungo;YAMOCHI-ONIZUKA Toshiko;YANAGISAWA Kouji;MATSUDA Isao;OTA Hidekazu;TOMOYASU Shigeru, Acta Haematol, 125(4):242 - 246, 2011年02月, 原著, 査読あり
  • Over-expression of CCL3 MIP-1alpha in a blastoid mantle cell lymphoma with hypercalcemia., HATTORI Norimichi;NAKAMAKI Tsuyoshi;ARIIZUMI Hirotsugu;HOMMA Mayumi;YAMOCHI-ONIZUKA Toshiko;OTA Hidekazu;TOMOYASU Shigeru, Eur J Haematol, 84(5):448 - 452, 2010年05月, 原著, 査読あり

講演・口頭発表等

  • 抗PD-1抗体で発症せず、抗PD-L1抗体投与後に血球貪食症候群様の免疫関連有害事象を発症した肺癌症例, 有泉　裕嗣;吉村　清;堀池　篤;平澤　優弥;石黒　智之;大熊　遼太朗;久保田　祐太郎;濵田　和幸;和田　聡;鶴谷　純司;角田　卓也, 第25回日本がん免疫学会総会, 2021年07月03日, 和歌山
  • PS良好PD-L1高発現NSCLCに対するPembrolizumab療法とプラチナ製剤併用＋Pembrolizumab療法の有効性の検討, 岸野　康成;楠本　壮二郎;堀池　篤;有泉　裕嗣;久保田　祐太郎;安藤　浩一;田中　明彦;大森　亨;角田　卓也;相良　博典, 第61回日本肺癌学会学術集会, 2020年11月12日, 岡山およびライブ配信・オンデマンド配信
  • スルファメトキサゾール・トリメトプリムによる無顆粒球症を発症した肺癌症例, 船越　晴喜;百　賢二;有泉　裕嗣;佐々木　忠徳, 第29回日本医療薬学会年会, 2019年11月02日, 福岡
  • 血液透析中の小細胞肺癌患者のイリノテカン導入と支持療法の選択に介入した1例, 加藤　梓;藤宮　龍祥;船越　晴喜;有泉　裕嗣;濵田　和幸;米澤　龍;竹安　葵;栗原　竜也;角田　卓也;佐々木　忠徳, 日本病院薬剤師会関東ブロック第49回学術大会, 2019年08月25日, 甲府
  • Expression of Olfactomedin-4 in pancreatic cancer and its clinical significance, OKUMA Ryotaro;KUBOTA Yutaro;HAMADA Kazuyuki;ISHIDA Hiroo;HIRASAWA Yuya;ARIIZUMI Hirotsugu;SATOH Etsuko;SHIDA Midori;WATANABE Makoto;TSURUTANI Junji;YOSHIMURA Kiyoshi;AOKI Takeshi;MURAKAMI Masahiko;NOROSE Tomoko;OHIKE Nobuyuki;TAKIMOTO Masafumi;TSUNODA Takuya;WADA Satoshi, 第17回日本臨床腫瘍学会学術集会 (JSMO 2019), 2019年07月18日, 京都
  • CHOP誘発性悪心および嘔吐の予防におけるpalonosetron単剤投与　第II相試験, SAITO Bungo;NAKASHIMA Hidetoshi;ABE Maasa;WATANUKI Megumi;BABA Yuta;MURAI So;FUJIWARA Shun;ARAI Nana;KAWAGUCHI Yukiko;KABASAWA Nobuyuki;TSUKAMOTO Hiroyuki;UTO Yui;ARIIZUMI Hirotsugu;YANAGISAWA Kouji;HATTORI Norimichi;HARADA Hiroshi;MORI Hiraku;NAKAMAKI Tsuyoshi, 第78回日本血液学会学術集会, 2016年10月13日, 横浜
  • A Cese report of management including perinatal genetic counseling for May Hegglin Anomaly in pregnancy that low platelets counts made the opportunity to diagnose., YAMASHITA Yuka;MATSUURA Rei;OIKAWA Yoshie;HAMADA Shoko;ARIIZUMI Hirotsugu;ODAWARA Kei;KOYANO Maya;NISHII Shogo;MURAMOTO Tsutomu;TAKENAKA Shin;NAKAYAMA Ken;MATSUMOTO Kaori;ICHIHARA Mitsuyoshi;SASAKI Yasushi;SHIRATO Nahoko;MATSUOKA Ryu ;OGAWA Kouichi;SEKIZAWA Akihiko;KUNISHIMA Shinji, ICHG 2016 : The 13th International Congress of Human Genetics, 2016年04月05日, Kyoto
  • Non-inferiority of vindesine vs vincristine R-CHOP in propensity score-modified retrospective study, ARIIZUMI Hirotsugu;MORI Hiraku;HARADA Hiroshi;SAITO Bungo;ARAI Nana;KAWAGUCHI Yukiko;FUJIWARA Shun;KABASAWA Nobuyuki;TSUKAMOTO Hiroyuki;UTO Yui;YANAGISAWA Kouji;HATTORI Norimichi;SAKASHITA Akiko;NAKAMAKI Tsuyoshi, 第77回日本血液学会学術集会, 2015年10月16日, 金沢
  • 化学療法後に中枢性塩類喪失症候群を合併したCNS非浸潤NK/T細胞腫瘍, 有泉　裕嗣;宇藤　唯;東　礼美;原田　浩史;佐々木　陽介;岸本　浩次;磯邊　友秀;塩沢　英輔;光谷　俊幸;瀧本　雅文;大池　信之;森　啓, 第72回神奈川血液研究会, 2015年09月05日, 横浜
  • Comparing the number of R-CHOP-like therapy cycles (6 vs. 8 cycles) for DLBCL using propensity score-modified analysis., ARIIZUMI Hirotsugu;Saito Bungo;Uto Yui;Hattori Norimichi;Yanagisawa Kouji;Nakashima Hidetoshi;Harada Hiroshi;Mori Hiraku;NAKAMAKI Tsuyoshi, 第12回日本臨床腫瘍学会学術集会, 2014年07月18日, 福岡
  • Scoring system using age, C-reactive protein, hemoglobin, and albumin (ACHA) for predicting outcomes of diffuse large B-cell lymphoma in the rituximab-era, ARIIZUMI Hirotsugu;SAITO Bungo;SHIOZAWA Eisuke;UTO Yui;HATTORI Norimichi;YANAGISAWA Kouji;NAKASHIMA Hidetoshi;HARADA Hiroshi;MORI Hiraku;NAKAMAKI Tsuyoshi, 55th American Society of Hematology annual meeting and exposition, 2013年12月09日, New Orleans
  • Soluble IL-2R levels predict survival following MCEC preconditioning and auto-PBSCT for lymphoma., ARIIZUMI Hirotsugu;SAITO Bungo ;UTO Yui;HATTORI Norimichi;NAKASHIMA Hidetoshi;YANAGISAWA Kouji;HARADA Hiroshi;NAKAMAKI Tsuyoshi;MORI Hiraku, 第75回日本血液学会学術集会, 2013年10月12日, 札幌
  • 大細胞型B細胞リンパ腫における初診時総鉄結合能(TIBC)の予後予測因子としての有用性, 有泉　裕嗣;宇藤　唯;服部　憲路;中嶋　秀人詞;齋藤　文護;柳沢　孝次;原田　浩史;森　啓;友安　茂;中牧　剛, 第37回鉄バイオサイエンス学会学術集会, 2013年09月08日
  • Myeloproliferative neoplasm with JAK2 V617F mutation and JAK2 intron 14 deletion, ARIIZUMI Hirotsugu;FUKUCHI Kunihiko;NAKAMAKI Tsuyoshi;YANAGISAWAKouji;NAKASHIMA Hidetoshi;MAEDA Takashi;SAITO Bungo;HARADA Hiroshi;MORI Hiraku;TOMOYASU Shigeru, 第74回日本血液学会学術集会, 2012年10月20日, 京都
  • IgA型モノクローナル蛋白血症を認めた眼付属器原発MALTリンパ腫の2例, 本間　まゆみ;有泉　裕嗣;塩沢　英輔;矢持　淑子;瀧本　雅文;高橋　学;太田　秀一, 第99回日本病理学会総会, 2010年04月27日, 東京

Copyright © MEDIA FUSION Co.,Ltd. All rights reserved.